Evidence & regulatory context
- Mechanism
- Estrogen receptor alpha agonist (AGONIST)
- Target
- CHEMBL206
- Injury models
- TBI
- Reported indication
- Not recorded
- First approval
- 1979
- Development stage
- Not recorded
- ChEMBL record
- CHEMBL1405 ↗
- ChEMBL max phase
- 4 / 4 (development scale, not regulatory approval)
- Synonyms
- Estrone; Folliculin; Theelin; Estradiol metabolite E1
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatTBIControlled cortical impactSprague-DawleyMale0.5 mg/kg30 min after severe traumatic brain injury
Model: Controlled cortical impact to the right parietal cortex after craniotomy
Estrone reduced cortical lesion volume, neuronal injury, TUNEL positivity and beta-amyloid, and increased phospho-ERK1/2, phospho-CREB and BDNF.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.
